

# VTE prophylaxis in nail surgery

Stella Harvey MSc FHES

Senior Lecturer in Podiatry



VTE

DVT

PE




NHS (2020)



Merschel (2021)

# Virchow's Triad



# Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism

NICE guideline [NG89] Published: 21 March 2018 Last updated: 13 August 2019

## All patients

- 1.1.1 Assess all patients to identify the risk of venous thromboembolism (VTE) and bleeding (see the [recommendation for all medical patients](#), [for all surgical patients](#), [for all pregnant women and all women who gave birth or had a miscarriage or termination of pregnancy in the past 6 weeks](#), [for all people admitted to the critical care unit](#) and [for all acute psychiatric patients](#)). [2018]

## RISK ASSESSMENT FOR VENOUS THROMBOEMBOLISM (VTE)

All patients should be risk assessed on admission to hospital. Patients should be reassessed within 24 hours of admission and whenever the clinical situation changes.

### STEP ONE

Assess all patients admitted to hospital for level of mobility (tick one box). All surgical patients, and all medical patients with significantly reduced mobility, should be considered for further risk assessment.

### STEP TWO

Review the patient-related factors shown on the assessment sheet against **thrombosis** risk, ticking each box that applies (more than one box can be ticked).

Any tick for thrombosis risk should prompt thromboprophylaxis according to NICE guidance.

The risk factors identified are not exhaustive. Clinicians may consider additional risks in individual patients and offer thromboprophylaxis as appropriate.

### STEP THREE

Review the patient-related factors shown against **bleeding risk** and tick each box that applies (more than one box can be ticked).

Any tick should prompt clinical staff to consider if bleeding risk is sufficient to preclude pharmacological intervention.

Guidance on thromboprophylaxis is available at:

National Institute for Health and Clinical Excellence (2010) *Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital*. NICE clinical guideline 92. London: National Institute for Health and Clinical Excellence.

<http://www.nice.org.uk/guidance/CG92>

This document has been authorised by the Department of Health  
Gateway reference no: 10278

## RISK ASSESSMENT FOR VENOUS THROMBOEMBOLISM (VTE)

Mobility – all patients (tick one box)	Tick		Tick		Tick
Surgical patient		Medical patient expected to have ongoing reduced mobility relative to normal state		Medical patient NOT expected to have significantly reduced mobility relative to normal state	
Assess for thrombosis and bleeding risk below				Risk assessment now complete	

Thrombosis risk			
Patient related	Tick	Admission related	Tick
Active cancer or cancer treatment		Significantly reduced mobility for 3 days or more	
Age > 60		Hip or knee replacement	
Dehydration		Hip fracture	
Known thrombophilias		Total anaesthetic + surgical time > 90 minutes	
Obesity (BMI >30 kg/m <sup>2</sup> )		Surgery involving pelvis or lower limb with a total anaesthetic + surgical time > 60 minutes	
One or more significant medical comorbidities (eg heart disease; metabolic, endocrine or respiratory pathologies; acute infectious diseases; inflammatory conditions)		Acute surgical admission with inflammatory or intra-abdominal condition	
Personal history or first-degree relative with a history of VTE		Critical care admission	
Use of hormone replacement therapy		Surgery with significant reduction in mobility	
Use of oestrogen-containing contraceptive therapy			
Varicose veins with phlebitis			
Pregnancy or < 6 weeks post partum (see NICE guidance for specific risk factors)			

Bleeding risk			
Patient related	Tick	Admission related	Tick
Active bleeding		Neurosurgery, spinal surgery or eye surgery	
Acquired bleeding disorders (such as acute liver failure)		Other procedure with high bleeding risk	
Concurrent use of anticoagulants known to increase the risk of bleeding (such as warfarin with INR >2)		Lumbar puncture/epidural/spinal anaesthesia expected within the next 12 hours	
Acute stroke		Lumbar puncture/epidural/spinal anaesthesia within the previous 4 hours	
Thrombocytopenia (platelets < 75x10 <sup>9</sup> /l)			
Uncontrolled systolic hypertension (230/120 mmHg or higher)			
Untreated inherited bleeding disorders (such as haemophilia and von Willebrand's disease)			

# Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism

NICE guideline [NG89] Published: 21 March 2018 Last updated: 13 August 2019

## All patients

- 1.1.1 Assess all patients to identify the risk of venous thromboembolism (VTE) and bleeding (see the [recommendation for all medical patients, for all surgical patients, for all pregnant women and all women who gave birth or had a miscarriage or termination of pregnancy in the past 6 weeks, for all people admitted to the critical care unit and for all acute psychiatric patients](#)). [2018]
- 1.1.6 Balance the person's individual risk of VTE against their risk of bleeding when deciding whether to offer pharmacological thromboprophylaxis to surgical and trauma patients. [2018]
- 1.3.5 Use anti-embolism stockings that provide graduated compression and produce a calf pressure of 14 mmHg to 15 mmHg. (This relates to a pressure of 14 mmHg to 18 mmHg at the ankle and is in line with the [British Standard Institution's BS 661210:2018 Specification for graduated compression hosiery, anti-embolism hosiery and graduated support hosiery](#).) [2010]
- 1.10.3 Do not routinely offer pharmacological or mechanical VTE prophylaxis to people undergoing a surgical procedure with local anaesthesia by local infiltration with no limitation of mobility. [2010]

# Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism

NICE guideline [NG89] Published: 21 March 2018 Last updated: 13 August 2019


## Foot and ankle orthopaedic surgery

1.11.14 Consider pharmacological VTE prophylaxis for people undergoing foot or ankle surgery:

- that requires immobilisation (for example, arthrodesis or arthroplasty); consider stopping prophylaxis if immobilisation continues beyond 42 days (see the [recommendation on lower limb immobilisation](#)) or
- when total anaesthesia time is more than 90 minutes or
- the person's risk of VTE outweighs their risk of bleeding. [2018]

## Lower limb immobilisation

Any clinical decision taken to manage the affected limb in a way that would prevent normal weight-bearing status or use of that limb, or both.



Moore et al (2012)

# THE AMAZING NEW ADVENTURES OF THE COAGULATION CASCADE

25¢ 92 MAY 1954

PRESENTING THE EPIC TALE OF FIBRINOGEN AND THE SEVERED FINGER!

### PRIMARY HEMOSTASIS (THE BODY'S FIRST RESPONSE TO INJURY)

**VASOCONSTRICTION**  
1. ENDOTHELIAL DAMAGE CAUSES CELLS TO RELEASE ENDOTHELIN.  
2. ENDOTHELIN AND THE NEURAL STIMULATION REFLEX CAUSE DAMAGED BLOOD VESSELS TO CONSTRICT & REDUCE BLOOD LOSS.

**COLLAGEN**  
1. THE COLLAGEN IN DAMAGED CELLS IS EXPOSED (COLLAGEN IS A STRUCTURAL PROTEIN IN HUMAN CONNECTIVE TISSUE).  
2. EXPOSED COLLAGEN BINDS VWF FACTOR. VWF IS A GLYCOPROTEIN NORMALLY PRESENT IN BLOOD PLASMA.  
3. PLATELETS BIND TO VWF VIA THE  $\alpha_{IIb}$  RECEPTOR.

**PLATELET PLUG FORMATION**  
1. THE COLLAGEN IN DAMAGED CELLS IS EXPOSED (COLLAGEN IS A STRUCTURAL PROTEIN IN HUMAN CONNECTIVE TISSUE).  
2. EXPOSED COLLAGEN BINDS VWF FACTOR. VWF IS A GLYCOPROTEIN NORMALLY PRESENT IN BLOOD PLASMA.  
3. PLATELETS BIND TO VWF VIA THE  $\alpha_{IIb}$  RECEPTOR.

**UNACTIVATED PLATELETS**  
4. WHEN PLATELETS BIND TO VWF THEY UNDERGO A CONFORMATIONAL CHANGE. DURING THIS TIME MORE AND MORE PLATELET CELLS ARE BINDING TO THE INJURY SITE.

**ACTIVATED PLATELETS**  
ADP AND TXA<sub>2</sub> STIMULATES PROSTAGLANDIN PRODUCTION IN NORMAL ENDOTHELIUM (STOP PLATELET AGGREGATION).  
5. IN ADDITION TO A CONFORMATIONAL CHANGE, PLATELETS ALSO BEGIN TO SECRETE ADP, CA<sup>2+</sup>, AND TXA<sub>2</sub>. THE RELEASED ADP HELPS PLATELETS ADHERE TO THE INJURED ENDOTHELIUM ONLY.

**TEMPORARY PLUG**  
6. THE LINKED PLATELETS CREATE A TEMPORARY PLUG THAT STOPS BLEEDING. THE PLUG IS FRAGILE AND EASILY BROKEN.

**THE FANTASTIC COMPONENTS OF HUMAN BLOOD**  
BLOOD CONTAINS RED BLOOD CELLS, THROMBOCYTES, SEVERAL LEUCOCYTES TYPES, DENDRITIC CELLS, AND PLASMA.  
MONOCYTES HAVE A SINGLE LARGE NUCLEUS.  
LYMPHOCYTES INCLUDE B, T, AND NK CELLS.  
NEUTROPHILS HAVE A MULTI LOBED NUCLEUS.  
EOSINOPHILS HAVE A DOUBLE LOBED NUCLEUS.  
BASOPHILS HAVE DENSE GRANULES THROUGHOUT.

**ABO CLASSIFICATION**  
A ANTIGEN, B ANTIGEN, BOTH A & B ANTIGEN, NO ABO ANTIGEN.

**RH CLASSIFICATION**  
RH+ (MOTHERS MUST BE TREATED WITH RHO IMMUNOGLOBULIN AFTER EACH PREGNANCY TO AVOID ANTI-D BLOOD FORMATION), RH- (NO RHO) ANTIGEN.

### SECONDARY HEMOSTASIS

**ABOUT THE PATHWAY**  
SECONDARY HEMOSTASIS IS THE RESPONSE OF THE COAGULATION SYSTEM TO AN INJURY. THE PROCESS IS NECESSARY TO CONTROL BLOOD LOSS FROM LARGE WOUNDS, AND THE FINAL RESULT IS THE FORMATION OF A BLOOD CLOT. IN CONTRAST, PRIMARY HEMOSTASIS ONLY INVOLVES PLATELETS AND THE VASCULAR SYSTEM, AND CAN ONLY CONTROL BLOOD FLOW FROM MINOR INJURIES TO SMALL BLOOD VESSELS.

**INTRINSIC COAGULATION PATHWAY (CONTACT ACTIVATION)**  
KIMWK, COLLAGEN, ETC. HELPS ACTIVATE THE COAGULATION CASCADE.  
XII → XIIa → XI → XIa → IX → IXa → VIII → VIIIa → X → Xa → II → IIa → I → Ia → FIBRIN → FIBRIN MESH

**EXTRINSIC COAGULATION / TISSUE FACTOR PATHWAY**  
THROMBOSPASTIN REQUIRES CA<sup>2+</sup> AND A PROSPHILIPIN. NORMAL ENDOTHELIAL CELLS RELEASE TSP1, A VWF INHIBITOR, TO RESTRICT CLOTTING.  
VII → VIIa → X → Xa → II → IIa → I → Ia → FIBRIN → FIBRIN MESH

**COMMON PATHWAY**  
X → Xa → II → IIa → I → Ia → FIBRIN → FIBRIN MESH

**ANTICOAGULANTS (INHIBITS FACTOR Xa)**  
INCLUDES LMWH (GREATEST EFFICIENCY), HEPARIN, DIRECT Xa INHIBITORS LIKE APOBENIN AND BIVALEXIDAN, AND FONDAPARINUX.

**ANTICOAGULANTS (INHIBITS THROMBIN)**  
THROMBIN INHIBITORS BIND TO 1 OR 2 OF THE 3 THROMBIN DOMAINS (AN ACTIVE SITE + 2 EXOSITES).

**IN-DEPTH TABLE OF COAGULATION FACTORS**


FACTOR	COMMON NAME & NOTES	HOW IT'S ACTIVATED
Factor I	FIBRINOGEN. PRECURSOR TO FIBRIN MONOMERS & FIBRIN MESH.	ACTIVATED BY FACTOR II
Factor II	PROTHROMBIN. A SERINE PROTEIN IN THE COMMON PATHWAY.	ACTIVATED BY FACTOR II
Factor III	TISSUE FACTOR / THROMBOSPASTIN. COFACTOR.	ACTIVATED BY FACTOR VII
Factor IV	CA <sup>2+</sup> . IONIC CALCIUM IS NECESSARY FOR MANY REACTIONS.	RELEASED FROM BLOOD CELLS
Factor V	LABILE FACTOR. COFACTOR IN THE COMMON PATHWAY.	ACTIVATED BY FACTOR X
Factor VI	STABLE FACTOR. SERINE PROTEIN IN THE EXTRINSIC COAGULATION PATHWAY.	ACTIVATED BY FACTOR VII
Factor VII	ANTITHROMBINIC FACTOR. SECONDARY CAUSES HEMOPHILIA A.	ACTIVATED BY FACTOR VII
Factor VIII	CHRISTMAS FACTOR. SECONDARY CAUSES HEMOPHILIA B.	ACTIVATED BY FACTOR X
Factor IX	STUART PROWER FACTOR. SERINE PROTEIN.	ACTIVATED BY FACTOR XI
Factor X	FA (PLASMA THROMBOSPASTIN ANTIGEN) OR X (ANTITHROMBIN C).	ACTIVATED BY FACTOR X
Factor XI	FIBRIN STABILIZING FACTOR. TRANSFORMS INTO VON WILLEBRAND FACTOR.	ACTIVATED BY FACTOR XI
Factor XII	VON WILLEBRAND FACTOR. THE "GLUE" - NOT BLOODING VWF.	ACTIVATED BY FACTOR XII

**HEPARIN (GREATEST EFFICIENCY)**  
LMWH (LOW MOLECULAR WEIGHT HEPARIN), ENOXAPARIN. DIRECT THROMBIN INHIBITORS (ARGATROBAN, BIVALIRUDIN, DESMATELAN). ACTIVE SITE.

**PLASMINOGEN**  
ACTIVATES PLASMIN. INHIBITS PLASMIN. PLASMIN.

**FIBRINOLYTIC SYSTEM**  
THE FIBRINOLYTIC SYSTEM BREAKS DOWN FIBRIN CLOTS. PLASMIN HYDROLYSES FIBRIN INTO SMALLER PRODUCTS. SLOWLY FIBRINOGEN AND CLOTTING MUST BE BALANCED DELICATELY DURING HEALING.


**FIBRIN DEGRADATION**  
FIBRIN DEGRADATION PRODUCTS ARE PHAGOCYTOSED.




Suresh (2023)

Lutz (2016)


### A Arterial Thrombosis



### B Venous Thrombosis




Koupenove et al (2017)



## Antiplatelets

- Aspirin
- Clopidogrel
- Dipyridamole
- Ticagrelor
- Cangrelor
- Prasugrel

# Reducing risk




## Anticoagulants

- Vitamin K antagonists
  - Warfarin
  - Acenocoumarol
  - Phenindione

## DOACs

- Apixaban
- Dabigatran
- Edoxaban
- Rivaroxaban

# Anti-coagulants




<https://www.mentimeter.com/app/presentation/alwj5gonoh5sgf2phyfeawdsk7xhh1bh/cbqa8xp2peih/edit>

# INR

- INR – International Normalised Ratio
- Time taken for blood to clot
- Normal = 1
- Target usually 2.5 – 3.5

- Stopping warfarin not usually justified for skin surgery
- INR <3.5 – no significant bleeding risk

(Bray, Adam & Wernham 2023)



Bleeding risk can refer both to the risk *of* bleeding and the risk *from* bleeding. We recommend the continuation of most anti-thrombotic agents for most skin surgery procedures. This is on the basis of evidence of a very low risk of morbidity and mortality from peri-operative bleeding, versus a variable risk of highly morbid or fatal thrombotic events associated with cessation.<sup>3-10</sup> Many surgeons already avoid stopping any antithrombotic drugs pre-operatively.<sup>8</sup> However the safety of this approach does depend on careful case selection, patient preparation and support, and the choice of therapy. Many high bleeding risk procedures could potentially be avoided altogether.

(Alcalay & Alcalay R (2004), Bordeaux et al (2011), Bray, Adam & Wernham (2023), Bray A, Wernham (2022), Iyengar et al (2020), Isted et al (2018), Lewis KG & Dufresne (2008), Otley (2003), Palamaras & Semkova (2015))



# An update for UK podiatrists performing toenail surgery on patients who are taking antithrombotic medications: it's about bleeding time

**Ian N Reilly**<sup>1,2</sup>. BSc, MSc, FCPodS, FFPM RCPS(Glasg). Consultant Podiatric Surgeon

**Toby Blandford**<sup>3</sup>. BSc(Hons). Private Practitioner

---

## Abstract

Nail surgery for the permanent removal of all or part of the nail unit can be performed via incisional or physically ablative techniques for conditions such as ingrown, mycotic, or dystrophic toenails. In the United Kingdom podiatric community, where phenol techniques are the standard of care for ablation of the matrix, there remains confusion about the management of patients undergoing nail surgery who are concurrently taking antithrombotic medication(s). The aim of this paper was to review the literature describing treatment strategies for antithrombosed patients undergoing nail surgery. However, having found limited evidence, the authors considered relevant and associated literature in the field of cutaneous/dermatological surgery and extrapolated those findings for patients undergoing nail avulsion surgery. A case-by-case risk assessment is warranted in all patients but **as a general rule, the podiatrist can perform nail surgery without the patient ceasing their antithrombotic medication.**

## Bleeding on the cutting edge: A systematic review of anticoagulant and antiplatelet continuation in minor cutaneous surgery

Alexander Isted<sup>1</sup>, Lilli Cooper<sup>2</sup>, R James Colville<sup>2</sup>

**Results:** 30 studies included data from over 14,000 patients, of which more than 5000 took regular AC/AP therapy. Thromboembolic events were rare but carry high morbidity and even mortality, and in these studies three events were associated with cessation of AC/AP. There was no increase in haemorrhagic complications in patients taking aspirin monotherapy, but evidence is conflicting regarding warfarin and clopidogrel monotherapy, which shows a small increase in rate of bleeding complications. However, no increase in wound dehiscence, graft failure, wound infection or cosmetic outcome was seen. Too few studies investigated DOAC use to draw reliable conclusions. Data are sparse in comparing multiple versus single AC/AP regimens. Use of skin grafts or local flaps may have a greater complication rate than direct closure in patients on one or more AC/AP, but evidence is limited.

**Conclusion:** A case-by-case risk assessment is warranted in all patients but where possible, clinicians should prioritise meticulous haemostasis over cessation of agents.

Authors	Study title	Outcomes
Blasdale & Lawrence (2008)	Perioperative international normalized ratio level is a poor predictor of postoperative bleeding complications in dermatological surgery patients taking warfarin	<ul style="list-style-type: none"> <li>No increase in intra-operative bleeding</li> <li>8% moderate or severe post-operative bleeding compared to no significant bleeding in control group</li> <li>Post-operative bleeding risk even increased when INR in therapeutic range</li> </ul>
Bordeaux et al (2011)	Prospective evaluation of dermatological surgery complications including patients on multiple antiplatelet and anticoagulant medications	<ul style="list-style-type: none"> <li>Patients on both clopidogrel and warfarin 40 times more likely to have bleeding complications</li> <li>All complications resolved without sequelae</li> <li>Anticoagulants and antiplatelets should be continued to avoid adverse thrombotic events</li> </ul>
Callahan et al (2012)	The management of antithrombotic medication in skin surgery	<ul style="list-style-type: none"> <li>Concerns re. bleeding but no life-threatening haemorrhage</li> <li>Potentially fatal cardiovascular events after cessation of antithrombotics</li> </ul>
Isted et al (2018)	Bleeding on the cutting edge: a systematic review of anticoagulant and antiplatelet continuation in minor cutaneous surgery	<ul style="list-style-type: none"> <li>No increase in haemorrhagic complications in patients on aspirin monotherapy</li> <li>Small increased risk in rate of bleeding complications in warfarin and clopidogrel monotherapy</li> <li>No increase in wound dehiscence/graft failure/infection/cosmetic outcome</li> <li>Sparse data on multiple vs single regimens and DOACs</li> </ul>

(Adapted from Reilly & Blandford 2021)



# ROYAL COLLEGE of PODIATRY

The use of anticoagulants should not prevent nail surgery, assuming the patient is suitable in all other respects, although the patient should be alerted that post-operative bleeding may be prolonged and their advised aftercare regime modified to reflect this. Recorded INR (International Normalised Ratio - a measure of the clotting time) values vary in accordance with the patient's individual condition and the higher the INR value, the longer the blood will take to form a clot; in many anti-coagulated cases the INR is maintained by warfarin therapy between 2-3, meaning that the clotting process will take approximately 2-3 times as long as normal (i.e. approximately 10-15mins, rather than the normal 5 minutes). Stopping the use of anticoagulant medication or avoiding surgery is not usually justified in these patients (see **BSDS Guidance**).



**Risk factors for significant post-operative bleeding events (in no particular order)**

**General patient factors**

- Previous post-op bleeding episode
- Unable or unwilling to rest post-op
- Poor home support if bleeds
- Bleeding tendency
- Age >65

**General risk of bleeding by procedure type (highest to lowest risk):**

Secondary intention wounds following excision

Local flaps

Grafts

Direct closure

Curettage and electrocautery

(Bray, Adam & Wernham 2023)

# Patient selection

## History

- Medical
- Surgical
- Drug



## Assessment

- Vascular
- Neurological
- Social
- Clinical need







Septodont (2023)

# Mechanical prophylaxis



Mild venous insufficiency



Corona phlebectatica paraplantis



Pinpoint haemosiderin pigmentation



Haemosiderosis and varicose veins



Pressure erythema over incompetent valves



Haemosiderosis and varicose veins

Caesar (2020)



Gee & Doyle (2015)



# Are compression stockings unnecessary?

Use as an adjunct to pharmaco-thromboprophylaxis in surgery

## Summary



Within the study population, pharmaco-thromboprophylaxis alone is non-inferior to a combination of pharmaco-thromboprophylaxis plus graduated compression stockings

## Population



1888 participants

Venous thromboembolism risk at baseline:  
Moderate: 15.9%, High: 84.1%

63.3% women

Adult elective surgical inpatients

## Study design



Randomised controlled trial



Single blinded

Randomisation allocation was 1:1 between intervention and control

## Comparison

### Intervention

Low molecular weight heparin **only**



948\*

### Control

Standard care

Low molecular weight heparin **and** graduated compression stockings



940†

## Outcomes

Venous thromboembolism occurrence

1.7%

Risk difference, % 95% CI

0.30 -0.65 to 1.26;  
P<0.001 for non-inferiority

1.4%

### Primary outcome

Venous thromboembolism: imaging confirmed lower limb deep vein thrombosis with or without symptoms, or pulmonary embolism with symptoms within 90 days of surgery

### Significance

Prespecified non-inferiority margin of 3.5%


# The Future

- Peroneal nerve neuromuscular stimulation  
(Tucker et al 2010)



Geko - Queen Mary University of London (2013)

- AI  
(Selby et al, 2018); Wang et al, 2021)
- ? Risk prediction
- ? Clinical decision support
- ? Monitoring and early detection
- ? Personalised treatment plans
- ? Data integration and analysis
- ? Patient education and engagement  
(Chat GPT 2023)



<https://www.mentimeter.com/app/presentation/alz8ppri86kpunvxczk5m4b9mnwmimrr/pztj5gyr3nqs/edit>

# References

- Alcalay, J; Alkalay, R (2004) Controversies in perioperative management of blood thinners in dermatologic surgery: continue or discontinue? *Dermatol Surg* 30;8:1091-4
- Bordeaux, JS; Martires, KJ; Goldberg, D; Pattee, SF; Fu, P; Maloney, ME (2011) Prospective evaluation of dermatologic surgery complications including patients on multiple antiplatelet and anticoagulant medications.. *J Am Acad Dermatol* 65;576-83
- Bray, Adam; Wernham, Aaron (2023) BSDS guidance on antirhombotics and skin surgery 2023 *British Society for Dermatological Surgery* Available from: <https://bsds.org.uk/wp-content/uploads/2023/08/BSDS-antithrombotics-and-skin-surgery-guideline-text-08.08.23.pdf> [Accessed 11/10/23]
- Bray, Adam; Wernham, Aaron GH (2022) Anticoagulation survey and guideline update. BAD July (BSDS SIG)
- Caesar, Jenny (2020) Venous insufficiency *DermNet NZ* Available from: <https://dermnetnz.org/topics/venous-insufficiency/> [Accessed 20/01/21]
- Gee, Emma; Doyle, Cara (2015) Best practice in the use of VTE prevention methods *Nursing Times* 111;16:12-24
- Iyengar, S; Yeager, DG; Cohen, JL; Ozog, DM (2020) Update and Review of Bleeding Considerations in Dermatologic Surgery: Anticoagulants and Antiplatelets. *Dermatol Surg* 46;2:192-201
- Isted, A; Cooper, L; Colville, RJ (2018) Bleeding on the cutting edge: A systematic review of anticoagulant and antiplatelet continuation in minor cutaneous surgery. *J Plast Reconstr Aesthet Surg* 71;4:455-467
- Koupenove, Mila; Kehrel, Beate E; Corkrey, Heather A; Freedman, Jane E (2017) Thrombosis and platelets: an update *European Heart Journal* 28;785-791
- Lewis, KG; Dufresne, RG Jr. (2008) A meta-analysis of complications attributed to anticoagulation among patients following cutaneous surgery *Dermatol Surg* 34;2:160-4
- Lutz, Eleanor (2016) The amazing new adventures of the coagulation cascade Nerdcore Medical Available from: <https://store.nerdcoremedical.com/blogs/news/new-poster-the-coagulation-cascade> [Accessed 17/11/23]
- Merschel, Michahel (2021) Pulmonary embolism is common and can be deadly, but few know the signs *American Heart Association News* Available from: <https://www.heart.org/en/news/2021/11/23/pulmonary-embolism-is-common-and-can-be-deadly-but-few-know-the-signs> [Accessed 11/10/23]
- Moores, Carl; Nimmo, Alistair F; Morrison, Gary A (2012) Haemostasis and thrombosis *Core Topics in Vascular Anaesthesia* Cambridge University Press Ch 8;71-79 DOI: <https://doi.org/10.1017/CBO9780511736537.009>
- NHS (2020) DVT (deep vein thrombosis) Available from: <https://www.nhs.uk/conditions/deep-vein-thrombosis-dvt/> [Accessed 22/01/21]
- NICE (2019) Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism Available from: <https://www.nice.org.uk/guidance/ng89/chapter/Recommendations> [Accessed 17/11/23]
- Otley, CC (2003) Continuation of medically necessary Aspirin and Warfarin During Cutaneous Surgery. *Mayo Clin Proc.* 78:1392-1396
- Queen Mary University of London (2013) A medical device to prevent deep vein thrombosis, developed by researchers at Queen Mary, University of London, has won two awards at the Innovations in Cardiovascular Interventions (ICI) conference in Tel Aviv Available from: <https://www.qmul.ac.uk/media/news/2013/smd/medical-device-to-prevent-dvt-wins-innovation-award.html> [Accessed 17/11/23]
- Palamaras, I; Semkova, K (2015) Perioperative management of and recommendations for antithrombotic medications in dermatological surgery. *Br J Dermatol* 172;597-605
- Reilly, Ian N; Blandford, Toby (2021) An update for UK podiatrists performing toenail surgery on patients who are taking antithrombotic medications: it's about bleeding time *Preprints* DOI: <https://doi.org/10.20944/preprints202105.0559.v1>
- Royal College of Podiatry (2022) Nail Surgery Guidelines Available from: <https://membersarea.rcpod.org.uk/podiatric-practice/professional-resources-area/guidelines> [Accessed 20/11/23]
- Selby, Luke V; Narain, Wazim R; Russo, Ashley; Strong, Vivian E; Stetson, Peter (2018) Autonomous detection, grading and reporting of post-operative complications using natural language processing *Surgery* 164;6:1200-1305
- Septodont (2023) Lignospan special Available from: <https://www.septodont.co.uk/product/pain-management-lignospan-special/> [Accessed 17/11/23]
- Shalhoub, J; Lawton, R; Hudson, J; Baker, C; Bradbury, A; Dhillon, K et al. (2020) Graduated compression stockings as adjuvant to pharmaco-thromboprophylaxis in elective surgical patients (GAPS study): randomised controlled trial *BMJ* 369 :m1309 doi:10.1136/bmj.m1309
- Suresh, Rithika (2023) The blood coagulation pathway and related disorders *Assay Genie* Available from: <https://www.assaygenie.com/blog/the-blood-coagulation-pathway-and-related-disorders> [Accessed 17/11/23]
- Tucker, AT; Maass, A; Bain, DS; Chen, L-H; Azzam, M; Dawson, H; Johnston, A Augmentation of venous, arterial and microvascular blood supply in the leg by isometric neuromuscular stimulation via the peroneal nerve *International Journal of Angiology* 19;1:e31-e37 doi: [10.1055/s-0031-1278361](https://doi.org/10.1055/s-0031-1278361)
- Ying; Jen Wei; Lin, Chee Yen; Anne, Cheong May (2022) Prothrombin Time *LearnHaem Haematology made simple* Available from: <https://www.learnhaem.com/courses/coag/lessons/coagulation-tests/topic/prothrombin-time-pt/> [Accessed 15/11/23]
- Wang, Qi; Yuan, Lili; Ding, Xianhui; Zhou, Zhiming (2021) Clinical and Applied Thrombosis/Haemostasis 27; doi: [10.1177/10760296211021162](https://doi.org/10.1177/10760296211021162)